A novel biomarker of fibrofatty replacement in dystrophinopathies identified by integrating transcriptome, magnetic resonance imaging, and pathology data.
Zhihao XieChang LiuChengyue SunYanyu LuShiyi WuYilin LiuQi WangYalan WanYikang WangMeng YuLingchao MengJianwen DengWei ZhangZhaoxia WangChunxia YangYun YuanZhiying XiePublished in: Journal of cachexia, sarcopenia and muscle (2023)
We identify CDKN2A expression as a novel biomarker of fibrofatty replacement, which might be a new target for antifibrotic therapy in dystrophinopathies.
Keyphrases
- magnetic resonance imaging
- poor prognosis
- electronic health record
- gene expression
- rna seq
- single cell
- computed tomography
- big data
- binding protein
- contrast enhanced
- stem cells
- long non coding rna
- machine learning
- dna methylation
- mesenchymal stem cells
- deep learning
- data analysis
- replacement therapy
- chemotherapy induced